N-(2,3-dihydroxypropyl) carbamoyl side chain: a potentially significant factor for recurrent iodinated contrast medium-related adverse drug reactions

Purpose To determine whether switching to contrast media based on the sharing of N -(2,3-dihydroxypropyl) carbamoyl side chain reduces the recurrence of iodinated contrast media (ICM)-associated adverse drug reactions (ADRs). Materials and methods This single-center retrospective study included 2133...

Full description

Saved in:
Bibliographic Details
Published in:European radiology 2024-10, Vol.34 (10), p.6444-6453
Main Authors: Kim, Pyeong Hwa, Suh, Chong Hyun, Jang, Eun Bee, Kim, Seonok, Park, Kye Jin, Park, Hyo Jung, Kim, Ah Young, Do, Kyung-Hyun, Lee, Jeong Hyun, Kim, Jin Hyoung, Jung, Ah Young, Lee, Choong Wook
Format: Article
Language:English
Subjects:
Aged
Contrast agents
Contrast Media
Contrast Media - adverse effects
Diagnostic Radiology
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Imaging
Internal Medicine
Interventional Radiology
Iodine - adverse effects
Male
Medicine
Medicine & Public Health
Middle Aged
Neuroradiology
Patients
Radiology
Recurrence
Retrospective Studies
Risk Factors
Side effects
Tomography, X-Ray Computed
Ultrasound
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To determine whether switching to contrast media based on the sharing of N -(2,3-dihydroxypropyl) carbamoyl side chain reduces the recurrence of iodinated contrast media (ICM)-associated adverse drug reactions (ADRs). Materials and methods This single-center retrospective study included 2133 consecutive patients (mean age ± SD, 56.1 ± 11.4 years; male, 1052 [49.3%]) who had a history of ICM-associated ADRs and underwent contrast-enhanced CT examinations. The per-patient and per-exam-based recurrence ADR rates were compared between cases of switching and non-switching the ICM from ICMs that caused the previous ADRs, and between cases that used ICMs with common and different carbamoyl side chains from ICMs that caused the previous ADRs. Downgrade rates (no recurrence or the occurrence of ADR less severe than index ADRs) were also compared. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were additionally performed. Results In per-patient analysis, switching of ICM showed a lower recurrence rate (switching, 10.4% [100/965] vs. non-switching, 28.4% [332/1168]), with the adjusted odds ratio (OR) of 0.27 (95% CI: 0.21, 0.34; p  
ISSN:1432-1084
0938-7994
1432-1084
DOI:10.1007/s00330-024-10730-7